BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...with AF Portola Pharmaceuticals Inc. (NASDAQ:PTLA) Betrixaban (small molecule) Phase III VTE Phase II Stroke TeaRx LLC...
BioCentury | Jan 27, 2014
Clinical News

TeaRxaban: Phase II started

...with Roche (see BioCentury, May 30, 2011). Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets Lovenox enoxaparin. TeaRx LLC...
BioCentury | May 30, 2011
Company News

TeaRx Ltd., Roche deal

...Roche granted newco TeaRx exclusive rights to develop and commercialize preclinical oral Factor Xa inhibitors in...
...develop and commercialize preclinical oral Factor Xa inhibitors in Russia and 11 other undisclosed countries. TeaRx...
...for the trials and is eligible for milestones and royalties. Financial terms were not disclosed. TeaRx...
Items per page:
1 - 3 of 3
BioCentury | Feb 27, 2014
Targets & Mechanisms

The XII factor

...with AF Portola Pharmaceuticals Inc. (NASDAQ:PTLA) Betrixaban (small molecule) Phase III VTE Phase II Stroke TeaRx LLC...
BioCentury | Jan 27, 2014
Clinical News

TeaRxaban: Phase II started

...with Roche (see BioCentury, May 30, 2011). Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets Lovenox enoxaparin. TeaRx LLC...
BioCentury | May 30, 2011
Company News

TeaRx Ltd., Roche deal

...Roche granted newco TeaRx exclusive rights to develop and commercialize preclinical oral Factor Xa inhibitors in...
...develop and commercialize preclinical oral Factor Xa inhibitors in Russia and 11 other undisclosed countries. TeaRx...
...for the trials and is eligible for milestones and royalties. Financial terms were not disclosed. TeaRx...
Items per page:
1 - 3 of 3